NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

OTC Markets · Biotechnology · USD

Synlogic, Inc. (SYBX) Stock Analysis

Synlogic, Inc. (SYBX) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

Last Updated: October 21, 2026

SYBX

$1.07

−$0.01 (−0.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SYBX with… →

SYBX Key Statistics

As of Oct 21, 2026
Trading
Open
$1.07
Previous Close
$1.08
52-Week Range
0.54–1.87
Volume
3.00
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.61
Valuation
Market Cap
$13.11M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.06
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$1.01M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.25M
1-Year Return
−39.89%
Dividend and dates
Avg Volume
76.05K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SYBX closed at $1.07, −39.89% over 1 year.

Synlogic, Inc. (SYBX) has a market capitalization of $13.11M.

In fiscal 2025, SYBX reported revenue of $0.00.

SYBX Stock Return by Calendar Year

Synlogic, Inc. (SYBX) 10-year return: what $10,000 became

1 year
$10,000 $6,011
−39.89%
5 years
$10,000 $258
−97.42%
10 years
$10,000 $66
−99.34%

If you had invested $10,000 in Synlogic, Inc. (SYBX) 10 years ago, at the close on October 21, 2016, it would have been worth $66 at the close on October 21, 2026: −99.34% in total, −39.50% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.46%
2025−20.00%
2024−63.64%
2023−66.23%
2022−68.60%
2021+12.04%
2020−16.28%
2019−63.20%
2018−27.73%
2017−23.02%
2016 (partial year)−57.66%

As of October 21, 2026.

SYBX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$1.01M—
2024$8.00K−$23.36M−291,987.5%
2023$3.37M−$61.27M−1,817.7%
2022$1.18M−$66.15M−5,605.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$3.53M−$1.01M—
2024$8.00K—−$15.78M−$23.36M−291,987.5%
2023$3.37M—−$55.16M−$61.27M−1,817.7%
2022$1.18M—−$67.42M−$66.15M−5,605.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

Synlogic, Inc. (SYBX) carries a market capitalisation of $13.11M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1.

The 52-week range on file runs from $0.54 to $1.87. SYBX last closed at $1.07 on October 21, 2026. That is −$0.01 (−0.93%) against the previous close. The latest close sits 98.15% above that 52-week low.

Financial Health

In fiscal 2025, Synlogic, Inc. reported revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $8.00K. The same year closed with a net loss of $1.01M. Earnings per share on a trailing basis come to −0.06.

Across the 4 fiscal years on file, revenue moves from $1.18M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.61. Annualized volatility over the trailing 10 years is 84.44%. Over the trailing twelve months the total return is −39.89%. Measured over 10 years, that is −39.50% a year compounded.

Growth & Income

The record shows no dividend for SYBX.

So far in 2026 the total return is −4.46%. The strongest complete calendar year on file is 2021 at +12.04%; the weakest is 2022 at −68.60%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

Synlogic, Inc. (SYBX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Synlogic, Inc. SYBX $13.11M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Synlogic, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Synlogic, Inc.

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.

Visit website →